Zomedica Corp. (ZOMDF) intrinsic value & 10-year financials
Zomedica Corp. (ZOMDF) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 66.8% a year to $32.0M, with an average return on invested capital of -141.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.08
- Market cap
- $77.5M
- Revenue (FY2025)
- $32.0M
- Revenue growth (10-yr CAGR)
- 66.8%
- ROIC (10-yr avg)
- -141.8%
- Free cash flow (FY2025)
- -$18.2M
ZOMDF 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $32.0M | -$81.9M | -$0.08 | -$18.2M | -263.4% | -56.5% |
| FY2024 | $27.3M | -$47.0M | -$0.05 | -$28.8M | -187.1% | -24.1% |
| FY2023 | $25.2M | -$34.5M | -$0.04 | -$16.5M | -125.4% | -12.9% |
| FY2022 | $18.9M | -$17.0M | -$0.02 | -$12.5M | -115.8% | -12.1% |
| FY2021 | $4.1M | -$18.4M | — | -$14.4M | -517.0% | -55.7% |
| FY2020 | $0 | -$16.9M | — | -$16.3M | — | 190.9% |
| FY2019 | — | -$19.8M | — | -$15.8M | — | -687.8% |
| FY2018 | — | -$16.6M | — | -$11.8M | — | -413.9% |
| FY2017 | — | -$8.1M | — | -$7.3M | — | -196.2% |
| FY2016 | — | -$5.7M | — | -$4.8M | — | -149.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Zomedica Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Zomedica Corp. has historically struggled to out-earn its cost of capital, averaging just -32.2% ROIC.
Zomedica Corp. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Zomedica Corp. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-2.66 per share.